Form 4: BioCardia CEO Peter Altman Acquires Shares in Open Market Transactions

BioCardia's President and CEO, Peter Altman, has acquired a total of 739 shares of common stock through open market purchases on January 29th and 30th, 2025.

Summary

• Peter Altman, the President and CEO of BioCardia, Inc., has reported purchasing shares of the company's common stock.
• On January 29, 2025, Mr. Altman acquired 500 shares at a weighted average price of $2.40 per share.
• On January 30, 2025, he purchased an additional 239 shares at a weighted average price of $2.38 per share.
• These transactions increased his direct holdings to 107,320 shares of BioCardia common stock.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting the facts of the share purchases. The CEO's purchase could be seen as a positive sign, but it's not a major event.

Positives

• The CEO's purchase of shares could be seen as a positive signal, indicating confidence in the company's future prospects.
• The purchases increase the CEO's stake in the company, aligning his interests with those of other shareholders.

Risks

• The document does not provide any information about the company's overall financial health or future performance.
• The share purchases are relatively small in the context of the company's overall market capitalization.

Industry Context

This type of filing is common for company insiders who trade shares of their own company. It is a routine disclosure required by the SEC to ensure transparency and prevent insider trading.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly traded companies, and these transactions are typical for executives.
• The size of the transactions is relatively small compared to the overall trading volume of the company's stock, suggesting it is not a major market event.

Stakeholder Impact

• The share purchases may have a minor positive impact on shareholder sentiment.
• The transactions do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

BioCardia, Peter Altman, share purchase, insider trading, common stock, open market, CEO